Which Class of ER Degrader Is Better?
The VERITAC-2 trial included patients with ER-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-), locally advanced or metastatic disease who had failed prior treatment with cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors and endocrine therapy, and no exposure to chemotherapy in the advanced setting.
Only a subset of the study cohort, those with estrogen receptor 1-mutant disease, experienced a statistically significant and clinically meaningful improvement in progression-free survival (PFS) when treated with vepdegestrant compared with patients treated with fulvestrant.
'These results support vepdegestrant as a potential monotherapy treatment option for patients with previously treated ESR1 -mutant ER+/HER2- advanced breast cancer,' said lead author Erika P. Hamilton, MD, a medical oncologist and director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute, Nashville, Tennessee, during a press conference for the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The findings were simultaneously published in the New England Journal of Medicine .
Vepdegestrant is not approved by the US Food and Drug Administration, but received fast-track status in February 2024 as monotherapy for this patient population. It is the first and only PROTAC ER degrader to be evaluated in a phase 3 clinical trial in breast cancer. PROTACs represent a novel class of therapeutic agents that harness the proteasome to selectively degrade target proteins.
'There's no established consensus for patients getting treatment in the second-line setting after progression on endocrine therapy and a CDK 4/6 inhibitor,' explained Hamilton. 'One of the mainstays of our treatment really has been fulvestrant, which clearly has some challenges. First, it's administered intramuscularly, and second, in a post-CDK 4/6 landscape, we know that progression-free survival is very short — on the order of less than 2 months.'
Besides fulvestrant, the oral SERD elacestrant was FDA-approved in January 2023, and other oral SERDs are in development, she noted.
Trial Design
The new trial included 624 patients with advanced ER+/HER2- disease that had progressed following one or two lines of endocrine therapy and a CDK 4/6 inhibitor.
'They could not have received fulvestrant already or chemotherapy, and patients had to have benefited from their previous line of endocrine therapy for at least 6 months to enter the study,' Hamilton noted.
Study participants were also stratified by the presence or absence of visceral disease, as well as the presence of an ESR1 mutation (n = 270). Such mutations are a common cause of acquired resistance found in approximately 40% of patients in the second-line setting, according to a press release from the drug developer.
Patients were randomly assigned 1:1 to 28-day treatment cycles of either 200 mg oral vepdegestrant once daily, or 500 mg intramuscular fulvestrant on day 1 and day 15 of the first cycle, and then on day 1 of each subsequent cycle.
The primary endpoint was PFS by blinded, independent central review, first in patients with ESR1 mutations and then in the entire cohort.
Key secondary endpoints were overall survival, objective response rate, and clinical benefit rate, which was defined as the rate of confirmed clinical or partial response at any time, or stable disease, nonclinical response, or nonprogressive disease for at least 24 weeks.
Vepdegestrant vs Fulvestrant
The study met its key primary endpoint, showing a median PFS of 5.0 months with vepdegestrant compared with 2.1 months with fulvestrant (hazard ratio [HR] 0.57; P < .001) in the 270 patients with ESR1 mutations. At 6 months, twice as many patients in the vepdegestrant arm remained progression-free compared with those in the fulvestrant arm (45.2% vs 22.7%). However, this primary endpoint was not significantly different between groups when calculated for the entire patient population (HR, 0.83; P = .07).
For the key secondary endpoints, among patients with ESR1 mutations, the clinical benefit rate was more than double in patients receiving vepdegestrant (42.1% vs 20.2%). Similarly, the objective response rate was more than four times higher (18.6% vs 4%)
Commenting in a press release, ASCO breast cancer expert Jane Lowe Meisel, MD, said that although the trial found that vepdegestrant worked better than fulvestrant in patients with ESR1 mutations, 'on average, patients did not have prolonged responses on either agent, highlighting the need for combination therapies and continued development in this space.' Meisel is co-director of Breast Medical Oncology at the Winship Cancer Institute of Emory University School of Medicine in Atlanta, Georgia.
'Overall survival was very immature at the time of this analysis, with only 20% of the anticipated events occurring,' added lead investigator Hamilton.
Treatment-emergent adverse events (TEAEs) led to discontinuation in 3% of patients taking vepdegestrant and 1% of patients taking fulvestrant. TEAEs leading to dose reductions occurred in 2% of the vepdegestrant group and none in the fulvestrant group.
The three most common AEs of any grade were fatigue (27% in vepdegestrant group, 16% fulvestrant group) and increased aspartate aminotransferase and alanine aminotransferase levels of any grade (14% vepdegestrant group, 10% fulvestrant group).
Oral SERDS vs Vepdegestrant Side Effects
Compared to oral SERDs, vepdegestrant has a favorable side effect profile, Hamilton said.
'Oral SERDs have prominent GI side effects as their most frequent side effect.' But, across all grades, rates of both vomiting and diarrhea were only 6% with vepdegestrant.
GI side effects tend to be more common, 'in the 30% or 40% range with oral SERDs,' she told Medscape Medical News .
Study discussant William John Gradishar, MD, emphasized the importance of reducing side effects.
' Vepdegestrant now joins a growing list of drugs that perform better than current standard of care monotherapy' in the ESR1 -mutant population, he noted in the session.
But the reality is that most of these drugs are being developed to be used in combination with targeted therapies, 'and increased toxicity can be expected with doublet therapy…Quality of life measures as experienced and reported by patients are critical, and even modest changes in symptom and functional domains should not be minimized,' said Gradishar, professor of breast oncology at Northwestern University Feinberg School of Medicine, Chicago, Illinois.
'Vepdegestrant has demonstrated compelling preclinical activity and encouraging early clinical data supporting its efficacy in degrading ER,' said Albert Grinshpun, MD, in an interview with Medscape Medical News .
Grinshpun, head of the Breast Cancer Service at Shaare Zedek Medical Center and The Hebrew University, Jerusalem, Israel, said his initial takeaway from the study is that 'vepdegestrant now stands alongside other oral SERDs, such as elacestrant and imlunestrant, in demonstrating superiority over fulvestrant, specifically in the context of ESR1 -mutant [disease].'
'Importantly, the treatment landscape for patients progressing on CDK 4/6 inhibitors is rapidly evolving, with a growing shift toward combination therapies rather than fulvestrant monotherapy,' he said. 'In my view, vepdegestrant has established itself as a promising endocrine backbone for future combination strategies. Its favorable toxicity profile makes it particularly well-suited for pairing with a range of targeted agents or even antibody-drug conjugates, including inhibitors of PIK3CA and KAT6 , in the pursuit of more effective therapeutic regimens.'
The study was jointly funded by Arvinas Estrogen Receptor, Inc. and Pfizer.
Hamilton disclosed consulting or advisory roles with Accutar Biotechnology (Inst), Arvinas (Inst), AstraZeneca (Inst), Circle Pharma (Inst), Daiichi Sankyo (Inst), Ellipses Pharma (Inst), Entos (Inst), Fosun Pharma (Inst), Genentech/Roche (Inst), Gilead Sciences (Inst), Janssen (Inst), Jazz Pharmaceuticals (Inst), Jefferies (Inst), Johnson & Johnson (Inst), Lilly (Inst), Medical Pharma Services (Inst), Mersana (Inst), Novartis (Inst), Olema Pharmaceuticals (Inst), Pfizer (Inst), Stemline Therapeutics (Inst), Tempus (Inst), Theratechnologies (Inst), Tubulis GmbH (Inst), Verascity Science (Inst), and Zentalis (Inst).
Hamilton has also received research funding from AbbVie (Inst), Accutar Biotech (Inst), Acerta Pharma (Inst), ADC Therapeutics (Inst), Akeso Biopharma (Inst), Amgen (Inst), Aravive (Inst), ArQule (Inst), Artios (Inst), Arvinas (Inst), AstraZeneca (Inst), AtlasMedx (Inst), BeiGene (Inst), Black Diamond Therapeutics (Inst), Bliss Biopharmaceutical (Inst), Boehringer Ingelheim (Inst), Bristol-Myers Squibb (Inst), Cascadian Therapeutics (Inst), Clovis Oncology (Inst), Compugen (Inst), Context Therapeutics (Inst), Cullinan Oncology (Inst), Curis (Inst), CytomX Therapeutics (Inst), Daiichi Sankyo (Inst), Dana-Farber Cancer Institute (Inst), Dantari (Inst), Deciphera (Inst), Duality Biologics (Inst), eFFECTOR Therapeutics (Inst), Eisai (Inst), Ellipses Pharma (Inst), Elucida Oncology (Inst), EMD Serono (Inst), Fochon Pharmaceuticals (Inst), Fujifilm (Inst), G1 Therapeutics (Inst), Genentech/Roche (Inst), Gilead Sciences (Inst), H3 Biomedicine (Inst), Harpoon (Inst), Hutchison MediPharma (Inst), Immunogen (Inst), Immunomedics (Inst), Incyte (Inst), Infinity Pharmaceuticals (Inst), Inspirna (Inst), InventisBio (Inst), Jacobio (Inst), K-Group Beta (Inst), Karyopharm Therapeutics (Inst), Kind Pharmaceuticals (Inst), Leap Therapeutics (Inst), Lilly (Inst), Loxo (Inst), Lycera (Inst), MabSpace Biosciences (Inst), Macrogenics (Inst), MedImmune (Inst), Mersana (Inst), Merus (Inst), Millennium (Inst), Molecular Templates (Inst), Myriad Genetics (Inst), Novartis (Inst), Nucana (Inst), Olema Pharmaceuticals (Inst), OncoMed (Inst), Oncothyreon (Inst), ORIC Pharmaceuticals (Inst), Orinove (Inst), Orum Therapeutics (Inst), Pfizer (Inst), PharmaMar (Inst), Pieris Pharmaceuticals (Inst), Pionyr (Inst), Plexxikon (Inst), Prelude Therapeutics (Inst), ProfoundBio (Inst), Radius Health (Inst), Regeneron (Inst), Relay Therapeutics (Inst), Repertoire Immune Medicines (Inst), Rgenix (Inst), Seagen (Inst), Sermonix Pharmaceuticals (Inst), Shattuck Labs (Inst), Silverback Therapeutics (Inst), Stem CentRx (Inst), Stemline Therapeutics (Inst), Sutro Biopharma (Inst), Syndax (Inst), Syros Pharmaceuticals (Inst), Taiho Pharmaceutical (Inst), TapImmune Inc. (Inst), Tesaro (Inst), Tolmar (Inst), Torque (Inst), Treadwell Therapeutics (Inst), Verastem (Inst), Zenith Epigenetics (Inst), and Zymeworks (Inst).
Meisel disclosed consulting or advisory roles with AstraZeneca, GE Healthcare, Genentech, Novartis, Olema Oncology, Pfizer, SeaGen, Sermonix Pharmaceuticals, and Stemline, and research funding from AstraZeneca (Inst), Olema Oncology (Inst), Pfizer (Inst), Seagen (Inst), and Sermonix Pharmaceuticals (Inst).
Grinshpun disclosed honoraria from GSK, Lilly, Novartis, and AstraZeneca, and travel from Roche, Pfizer, and AstraZeneca.
Gradishar disclosed consulting or advisory roles with AstraZeneca , Genentech/Roche, Gilead Sciences, Merck, Novartis, Pfizer.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
10 California Cities Where Home Prices Are Surging in 2025
Swaths of California are seeing housing prices drop, thanks largely to the combination of increased inventory and sky-high interest rates. Even markets that are typically somewhat immune to general trends and consistently robust — like Mountain View and San Diego — have softened over the past year. But there are still plenty of places in the Golden State where real estate prices are climbing. Find Out: Read Next: Consider the following 10 cities in California where home prices are surging. Most of these cities are already really expensive for housing, so even a seemingly modest increase in value can add well over $100,000 to a home's price. 10. Pasadena Average home value in June 2025: $1,216,844 Increase in value (percentage) year-over-year: 1.8% Increase in value (dollars) year-over-year: $21,516 Explore More: 9. Bakersfield Average home value in June 2025: $398,238 Increase in value (percentage) year-over-year: 2.0% Increase in value (dollars) year-over-year: $7,809 8. Torrance Average home value in June 2025: $1,184,834 Increase in value (percentage) year-over-year: 2.1% Increase in value (dollars) year-over-year: $24,370 7. Palo Alto Average home value in June 2025: $3,576,394 Increase in value (percentage) year-over-year: 2.2% Increase in value (dollars) year-over-year: $76,987 6. Visalia Average home value in June 2025: $395,417 Increase in value (percentage) year-over-year: 2.3% Increase in value (dollars) year-over-year: $8,890 5. Mission Viejo Average home value in June 2025: $1,212,384 Increase in value (percentage) year-over-year: 2.5% Increase in value (dollars) year-over-year: $29,570 4. Dana Point Average home value in June 2025: $1,690,917 Increase in value (percentage) year-over-year: 3.6% Increase in value (dollars) year-over-year: $58,758 3. Cupertino Average home value in June 2025: $3,083,634 Increase in value (percentage) year-over-year: 3.6% Increase in value (dollars) year-over-year: $111,011 2. Newport Beach Average home value in June 2025: $3,457,389 Increase in value (percentage) year-over-year: 3.6% Increase in value (dollars) year-over-year: $120,141 1. Saratoga Average home value in June 2025: $4,024,743 Increase in value (percentage) year-over-year: 4.4% Increase in value (dollars) year-over-year: $169,625 More From GOBankingRates 6 Popular SUVs That Aren't Worth the Cost -- and 6 Affordable Alternatives This article originally appeared on 10 California Cities Where Home Prices Are Surging in 2025
Yahoo
27 minutes ago
- Yahoo
Michael Jordan gave Charles Barkley 1 financial tip that made him millions
Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below. We adhere to strict standards of editorial integrity to help you make decisions with confidence. Some or all links contained within this article are paid links. Young athletes have been known to blow through their first big paycheck. Former NBA star Charles Barkley almost did, too — until Michael Jordan gave him one life-changing financial tip. In an episode of The Steam Room podcast, Barkley says he and Jordan were about to sign endorsement deals with Nike at roughly the same time. Barkley's deal was originally for $3 million, but before he signed on the dotted line, Jordan asked him one simple question: "Hey man, why you need all that money?" Don't miss Thanks to Jeff Bezos, you can now become a landlord for as little as $100 — and no, you don't have to deal with tenants or fix freezers. Here's how I'm 49 years old and have nothing saved for retirement — what should I do? Don't panic. Here are 5 of the easiest ways you can catch up (and fast) You don't have to be a millionaire to gain access to this $1B private real estate fund. In fact, you can get started with as little as $10 — here's how The conversation led Barkley to make a decision that could have cost him millions, but instead made him a fortune. Here's the game-changing money move that he learned from Jordan, and how you can apply it to your own wealth-building strategy. Equity over cash Although $3 million was no small sum, Jordan recognized that with the right strategy, Barkley could turn it into something much bigger. He told Barkley to renegotiate his contract and take only $1 million in cash and the rest in Nike stock options. After a brief discussion with his team, Barkley took the advice and set himself up for an immense windfall down the road. 'I actually made probably 10 times that amount of money and I'm still with Nike to this day,' Barkley proudly proclaimed. Barkley didn't mention if he still holds his Nike stake, but the stock is up a jaw-dropping 4,000% since his signature basketball sneaker, the Nike Air Force Max CB, debuted in 1994. His story highlights how gaining equity can be far more lucrative than a quick cash payout, especially when it's tied to a strong, growing business. Here's how you can apply this lesson to your investment strategy. Read more: Rich, young Americans are ditching the stormy stock market — Aiming for long-term growth Like Jordan and Barkley at the dawn of their respective careers, young investors should be more focused on capital appreciation and growth rather than immediate cash flow. This is why some financial advisors recommend using the Rule of 100 for age-appropriate asset allocation. To use this rule, subtract your age from 100 and the remainder represents the percentage of your portfolio that you should invest in stocks. So, if you're 30 years old, you would set aside 70% of your portfolio for stocks while 30% can be allocated to safe havens such as bonds. Another way to prioritize growth is to set aside a portion of your paycheck to invest in stocks every month. As of January, 2025, the personal savings rate is 4.60%, according to the Federal Reserve. By saving a greater portion of your income — say 15% — you could reach your financial goals faster. However, given the current economic climate, many don't have enough savings at the end of each month to invest in stocks. But that doesn't mean you can't harness the power of compounding interest. Rather than aiming to save up 15% of your paycheck each month, you could turn your spare change from everyday purchases into an investment opportunity with Acorns instead. Here's how it works: Once you link your debit and credit cards Acorns will round-up every purchase you make to the nearest dollar and set aside the excess. When the balance reaches $5 Acorns will then invest it in a smart investment portfolio comprising diversified ETFs. This way you can turn everyday purchases like a $4.25 cup of coffee into a $0.75 investment in your future. Just $3 worth of daily round-ups means $1,000 in savings in a year — and that's before compounding. You can get a $20 bonus investment from Acorns when you sign up. Meanwhile, young investors with a higher appetite for risk could instead focus on growth stocks rather than dividend-paying, blue-chip stocks. If you want to begin investing in individual stocks, but don't know where to start, consider consulting experts at Moby. Founded by a group of former hedge fund analysts, Moby aims to help investors find undervalued stock picks that could potentially deliver multi-bagger returns. To do so Moby delivers hedge-fund level stock market analysis in plain English straight to your inbox. Moby has a pretty successful track record — over the past four years, its stock picks have outperformed the S&P 500 index by 11.95%. And that's over the index's annualized returns of roughly 10% per year. What's more, over 75 stock recommendations from Moby have delivered returns of over 100%. Sign up today and become a smarter advisor within minutes. What to read next How much cash do you plan to keep on hand after you retire? Here are 3 of the biggest reasons you'll need a substantial stash of savings in retirement 5 simple ways to grow rich with US real estate — without the headaches of being a landlord. Start now with as little as $10 This tiny hot Costco item has skyrocketed 74% in price in under 2 years — but now the retail giant is restricting purchases. Here's how to buy the coveted asset in bulk Financial aid only funds about 27% of US college expenses — but savvy parents are using this 3-minute move to cover 100% of those costs Stay in the know. Join 200,000+ readers and get the best of Moneywise sent straight to your inbox every week for free. This article provides information only and should not be construed as advice. It is provided without warranty of any kind. Sign in to access your portfolio
CNET
28 minutes ago
- CNET
Do Contact Lenses Expire? Everything Eye Doctors Want You to Know About Replacing Your Contacts
If you wear contact lenses, you probably don't think much about them. But they're a relatively new invention -- in fact, the first disposable contact lens wasn't introduced until 1982. "We think of contact lenses as being so normal, but 100 years ago, nobody walked around with little pieces of plastic over their eyes," says ophthalmologist Dr. Robert Kinast, the vice chair of ophthalmology at Legacy Devers Eye Institute and co-founder of GentleDrop. "Contact lenses are foreign bodies and should be treated with respect," Kinast continues. In other words, it's important to take care of your contact lenses and replace them when they expire. To help, we consulted experts about contact lens expiration dates and eye health. How long do contacts last? The lifespan of your contact lenses depends on a few factors. Dr. Meenal Agarwal, optometrist and podcast host, explains, "Soft daily disposables are single-use, so you need to discard them after one day." At the other end of the spectrum, she says that "hard lenses can last one to two years with proper care." The most important rule, Agarwal says, is to always follow the replacement schedule recommended by your eye doctor. Soft lenses are the most commonly worn contact lenses, according to Dr. Jovi Boparai, ophthalmic surgeon and co-founder and CEO of CorneaCare. He explains that these lenses "range from daily disposables to weekly, biweekly or monthly." However, "Rigid gas permeable contact lenses can last much longer, ranging from months to a year." These lenses are made of hard plastic. While most contact lenses will last for the intended duration, some factors may shorten their lifespan. For instance, dust and smoke may cling to your lenses and make them unusable. If there is a wildfire in your area or a high allergen count and your lenses start to feel uncomfortable, you may want to toss them early. How to know if your contacts are expired The quickest way to gauge whether your contacts are expired is to look at the date on the box. Boarpai says that unopened contact lenses generally have a shelf life of one to four years from the date of manufacturing. Beyond reviewing the expiration date, you should pay attention to how your lenses look. According to Dr. Boparai, old lenses may show discoloration or damage. He also warns that expired contacts can develop deposits -- meaning a buildup of residue on the lenses. On the other hand, your contacts may still be expired, even if they look great. Agarwal warns, "The lenses may look the same as they did on the first day, but that doesn't mean they're still safe to use." In short, you should defer to the expiration date first, but also ditch your lenses if there is obvious damage or they become painful. Anna Gragert/CNET Expired contact lens symptoms It's easy to lose track of your lens-changing schedule when life gets busy. If that happens, your lenses may let you know they're expired before you even have a chance to track down the date on the box. "Wearing expired contacts can cause redness, pain or discomfort, irritation, blurry vision, excessive dryness and/or infections," Agarwal warns. You should take these symptoms as a red flag. The doctor advises, "If you experience any of these symptoms, remove the lenses and consult your eye doctor." According to Boparai, additional symptoms may include "burning, watery eyes, light sensitivity, discharge, foreign body sensation and eyelid swelling." Signs that your contacts are ready to be replaced It's worth noting that you won't always experience symptoms when your contacts are ready to be changed. Sticking to the appropriate schedule is vital, even if you think your contacts could last a few more weeks. As Agarwal explains, "Most of the time, you will not have any symptoms when your lenses are ready to be replaced." However, the doctor reiterates that if you've overworn contacts for a long time, you may notice vision problems, painful symptoms or "a torn or damaged lens and/or a buildup of deposits or debris on the lenses." This means it's definitely time to switch to a fresh pair. How often should I change my contact lenses? The simplest answer is to follow the recommended duration of use. Boparai reiterates that you should change lenses based on "the lifespan of the contact lenses as recommended by your eye doctor." You may also want to consider the length of time you're wearing your lenses per day. According to Optometrists Network, about half of all contact lens wearers don't comply with the wear schedule recommended by their doctors. This can lead to something called contact lens overwear syndrome, which occurs when your lenses obstruct your eyes' ability to absorb oxygen. Left untreated, you may experience bloodshot eyes, infection or a damaged cornea. Both doctors we spoke to insisted that you should never sleep in contacts unless it's recommended by a doctor. This may help prevent overwear syndrome and lower your risk of infections and ulcers. It also gives you an incentive to check your lenses each morning to make sure it's not time to change them to care for your contact lenses Proper care for your contacts not only helps maximize their lifetime but may also prevent eye infections. First and foremost, you should always handle your contact lenses with clean hands, according to the American Academy of Ophthalmology. The organization also recommends using a "rub and rinse" method each time you use your lenses. This means you should first rub your lens with clean fingers and then rinse it with a contact lens solution. Contact lenses carry an increased risk of eye inflammation and infection, Boparai says. He adds that proper contact lens hygiene includes rinsing the lenses for 10 to 20 seconds before wear and making sure you don't touch your cornea when adding or removing the lenses. Boparai also recommends changing your contact lens solution every day. Meenal emphasizes the importance of storing your lenses "in a clean case and replacing the case every three months." She warns that you should never use water or saliva to clean your contact lenses. How to prevent contact lens-related eye infections The most common eye infection associated with contact lenses is keratitis, which the Mayo Clinic describes as an inflammation of the cornea. And this infection happens a lot. The US Centers for Disease Control and Prevention analyzed contact lens-related infections between 2005 and 2015 and determined that "keratitis from all causes, including contact lens wear, results in approximately 1 million clinic and emergency department visits annually." The AAO says that wearing extended-wear lenses, sleeping in your lenses and keeping a dirty lens case can all make you vulnerable to this type of infection. The Mayo Clinic warns that poor contact lens hygiene allows for the growth of bacteria, fungi and parasites that can infect your cornea. Agarwal adds to this advice, explaining that contact lens wearers should never share or reuse lenses. She also warns that you should "avoid wearing contacts in pools, hot tubs or the shower," removing your lenses at the first sign of discomfort. And don't use saliva to clean your lenses, as Boparai warns this makes you more vulnerable to infection. What about colored contacts and costume contacts? Cosmetic contacts, especially non-prescription costume lenses, are dangerous to your eyes and the American Academy of Ophthalmology warns against wearing any contact lenses not prescribed to you by a medical professional. In fact, it's against the law to sell contact lenses without a prescription in the United States because of the risk of eye infections or permanent eye damage from poorly fitting or poorly manufactured lenses, which can damage wearers' eyes. There are prescription cosmetic lenses on the market, mostly used to hide eye problems present from birth, but those need to be made specifically for the wearer's eyes, and they'll come with guidance from your eye doctor as to how long you should wear them and when they'll need replacing. When to contact an eye doctor if you wear contact lenses The AAO says that patients who are at low risk for ocular disease should get an eye exam at least every two years until the age of 64, unless their doctor recommends more frequent exams. After the age of 65, annual eye exams are the standard. However, even if you're not high risk, you should see your eye doctor "as soon as possible if you experience eye pain, persistent redness or swelling, intolerance or discomfort with your lenses, sudden blurry vision, unusual discharge, excessive tearing and/or sensitivity to light," Agarwal said, adding that you should remove your lenses and not wear them again until your doctor gives you the go-ahead. Vision changes also call for another visit to the eye doctor, says Boparai. He emphasizes that if you have uncomfortable symptoms or vision loss, "Your eye doctor will help guide management to keep your eyes comfortable and clear." The bottom line When in doubt, don't overwear your contact lenses. You should throw them out as soon as they expire, start to hurt your eyes or appear damaged. Wearing lenses improperly isn't just uncomfortable -- it can also lead to serious infections. Don't be afraid to call your eye doctor if something seems wrong.
